| Literature DB >> 34375614 |
Skylar J Ferrara1, Priya Chaudhary2, Margaret J DeBell1, Gail Marracci2, Hannah Miller1, Evan Calkins2, Edvinas Pocius2, Brooke A Napier3, Ben Emery4, Dennis Bourdette2, Thomas S Scanlan5.
Abstract
Triggering receptor expressed on myeloid cells-2 (TREM2) is a cell surface receptor on macrophages and microglia that senses and responds to disease-associated signals to regulate the phenotype of these innate immune cells. The TREM2 signaling pathway has been implicated in a variety of diseases ranging from neurodegeneration in the central nervous system to metabolic disease in the periphery. Here, we report that TREM2 is a thyroid hormone-regulated gene and its expression in macrophages and microglia is stimulated by thyroid hormone and synthetic thyroid hormone agonists (thyromimetics). Our findings report the endocrine regulation of TREM2 by thyroid hormone, and provide a unique opportunity to drug the TREM2 signaling pathway with orally active small-molecule therapeutic agents.Entities:
Keywords: SARS-CoV-2; TREM2; innate immunity; neurodegeneration; therapeutics; thyroid hormone
Mesh:
Substances:
Year: 2021 PMID: 34375614 PMCID: PMC8818810 DOI: 10.1016/j.chembiol.2021.07.014
Source DB: PubMed Journal: Cell Chem Biol ISSN: 2451-9448 Impact factor: 8.116